Introduction
Most currently used vectors used for gene transfer in vivo can be classified into one class providing stable integration of the transgene into the host cell genome (eg adeno-associated viral vectors, retroviral vectors), [1] [2] [3] and another class which enters the target cell to persist in an episomal state outside of the host cell genome (eg adenoviral vectors). 4, 5 A third class of vectors has been envisaged, in which the vector persists as an episome with the capacity of limited self-replication. An interesting approach in realizing this novel type of vector is the development of 'human artifical chromosomes,' which in addition to the transgene expression cassette contain an origin of replication which is effective in mammalian cells, eg the latent replication origin of Epstein-Barr virus or certain mammalian chromosomal sequences. 6, 7 This general concept has been further developed by including sequences providing nuclear retention of the vector DNA. 8 In the case of viral vectors, self-replication could either mean neosynthesis of complete infectious viral particles in vector-transfected cells, or 'autoreplication' of the vector genomic DNA only, without synthesis of viral proteins except those essential for viral DNA neosynthesis. In the case of adenovectors those are single-strand DNAbinding protein DBP, adenoviral DNA polymerase AdPol, and preterminal protein pTP. 9, 10 Non-replicating, episomally persistent vector DNA should decay with time, whereas autoreplication-type vectors could, in principle, have unlimited stability. High transgene stabilities of 1 year and more have been reported in immunomodulated and in genetically immunodeficient hosts after adenovector-mediated gene transfer, [11] [12] [13] suggesting an inherently long half-life of the episomal vector DNA in the host cells in vivo. Other possible exlanations for the high stability are stabilization of the transgenic vector DNA by complexation with histones or similar proteins, or the above mentioned autoreplicaton of the vector genome due to residual activity of the adenoviral DNA replicating genes.
We tested the latter hypothesis by studying the replicative status of the genomes of different adenoviral vectors in non-premissive cell cultures (EAhy.926, COS7). Highly sensitive DNA metabolic labeling experiments conducted in quiescent, vector-transfected, nonpermissive cells showed high-level replication of wildtype adenoviral genome, as expected, but no replication of the vector DNA in several of the recombinant vectors tested ('type B'), as anticipated due to the extensive E1 deletion incorporated in these vectors. Unexpected was the finding of readily detectable autoreplication of vector genomic DNA in other vectors ('type A'), although neither type A nor type B vectors caused cytopathic effects or produced infectious viral progeny. Both types of vector are E1 region-deleted, and differences between the respective E3 regions were excluded by sequencing. However, sequencing of the respective E1 regions and different transgene expression cassettes showed a less extensive E1 deletion in type A vectors (nucleotide positions (np) 453-3333) as compared with type B vectors (np 325-3523). Transcriptional mapping of the vectors showed that autoreplication was associated with high transcriptional activity of four adenoviral genes (E1B-14k, adenoviral DNA polymerase, single-strand DNA-binding protein, E4-25k), 9, 14 in contrast to type B vectors. In addition to these 'wild-type' transcripts, 'irregular' recombinant transcripts were detected in autoreplication vectors which contain the transgenic cDNA in conjunction with adenoviral vector sequences. Exogenous or cryptic promotors appear to enhance (under certain conditions) the transcriptional activity of a viral vector in such a way that autoreplication of the vector genome occurs. The molecular conditions determining the level of transcriptional enhancement and autoreplication (precise structure of the vector E1 region, strength and type of promotor and termination signals, length and stability of transgenic cDNA) need to be further defined, however, before rational design of viral vectors with high autoreplication capacity based on adenoviral genes becomes possible. Viral autoreplication vectors have an important principal advantage over 'mammalian artificial chromosome'-type vectors with plasmid structure, 8 since they retain their elaborate apparatus for entry into the target cells resulting in high gene transfer rates. In summary, autoreplication capacity in non-permissive cells has been shown to be a novel feature of certain E1-deleted adenovectors with likely relevance for their stability in vivo, but possibly adverse consequences for target cell function or vector immunogenicity cannot be excluded. Full characterization of adenoviral vector systems should therefore include a description of their autoreplication capacity.
Results
Detection of autoreplication (DNA metabolic labeling studies) To investigate the potential of different E1-deleted adenoviral vectors for autoreplication of their genomes in nonpermissive cells, human EA.hy926 endothelial cells were transfected with these vectors at a multiplicity of infection (MOI) of 100. 293 cells which provide E1 helper functions, and the wild-type mutant Addl327 were used as 'positive controls'. Two different procedures have been used for the construction of E1-deleted vectors. The vectors Ad5CMVNOSIII, Ad5CMVcGKl␤, and Ad5CMVLuc have been developed by homologous recombination between pJM17 and pCMVI-based transfer plasmids carrying the respective transgene expression cassettes which resulted in an E1 deletion ranging from np 325-3523. The other procedure was in vitro ligation between RR5 and pZS2-based transfer plasmids carrying the expression cassettes, 13 which yielded an E1 deletion from np 453-3333 (for details see Figure 1 ). Metabolic labeling using 3 H-thymidine started 11 h after vector transfection of quiescent, thymidine-deprived EAhy.926 cell cultures, followed by total cellular DNA extraction, HindIII restriction and Southern blot analysis after 6 h of labeling. 
Detection of autoreplication (quantitative PCR studies)
To complement these vector DNA metabolic labeling experiments we analyzed the biological properties of type A versus type B vectors using an independent technical approach. A competitive quantitative PCR assay was developed to detect adenoviral vector DNA in relation to the cellular genomic housekeeping gene GAPDH. When this assay was applied to rapidly proliferating cell cultures transfected with different vectors, it provided quantitative data on vector DNA persistence in proliferating target cells. Figure 3 summarizes results of this type of experiment with EAhy.926 cells. There were significant differences in the quantity of adenovector DNA present on day 6 after transfection per copy of cellular genomic GAPDH gene. Since the copy number of GADPH genes detected is directly proportional to the number of cells in culture, the assay actually measures vector DNA copies per cell.
Analysis of cytopathic effects of the adenoviral vectors Confluent 293 cell monolayers providing E1 helper functions, and non-permissive EAhy.926 cell monolayers were transfected with the autoreplication ('type A') vectors RR5 or Ad5CMVFIX, or with the wild-type mutant Addl327 (MOI = 2). Five to 6 days after transfection, plaques appeared on all 293 cell monolayers, as expected due to their stable expression of E1 helper functions (Figure 4a ). In contrast, even after extended incubation periods up to 4 weeks EAhy.926 monolayers were neither lysed by the E1-deleted RR5 or Ad5CMVFIX vector, but only by Addl327, indicating lack of any cytopathic effect or production of infectious viral progeny from these E1-deleted 'autoreplication' vectors, even after extended periods of time (Figure 4a ). Significant cytotoxic effects were also not detectable by LDH release assay for any of the vectors in non-permissive cells (Figure 4b ), but more subtle alterations of cell functions (adhesion, migration, proliferation, signaling pathways) cannot be excluded so far.
Mechanism of autoreplication (DNA sequence analysis of different vectors)
The E3 region of RR5-based and pJM17-based vectors was PCR amplified for sequencing by using purified viral DNA, respectively, and primers immediately upstream and downstream of the E3 region. No differences between the two vector systems were found in this area. In a similar way, the E1 region and its immediate flanking sequences were amplified by using a primer upstream of the E1A-34k gene (Ad5-code) and another downstream of the E1B-14k gene (Ad5-E1anti). Figure 5 summarizes the results of these sequencing studies and also contains part of the wild-type adenovirus type 5 sequence for comparison. The sequence of the vector RR5 and its recombinants derived by using the transfer plasmid pZS2 (top line) is compared with that of recombinant vectors derived by homologous recombination between pJM17 and the transfer plasmid pCMVI (middle), and with wild-type Ad5 sequence (bottom line). Sequence numbering is given as in the adenovirus 5 wild-type sequence, wild-type sequences present in the vectors are boxed, (for details see also Figure 1 ) whereas the different deletions of the wild-type genome in the vectors are indicated by points ( Figure 5 ). Whereas the E1A region is completely deleted in both RR5-based and pJM17-based vectors, the E1B region is only partially deleted in both cases. In both cases the deletion includes the first base of the E1B-55k start codon, but whereas RR5-based vectors partially retain a 3Ј-fragment of the E1B-55k gene ranging from np 3334 to the stop codon at np 3508, pJM17-based constructs are deleted beyond the stop codon up to np 3523. The complete E1B-14k gene coding sequence starting at np 3608 is conserved in both cases.
Mechanism of autoreplication (transcriptional activity of different vectors)
For Northern blot analysis of adenoviral genomic transcripts 16 h after transfection of the non-permissive EAhy.926 cells with different adenovectors (MOI = 100), 20 g of total cellular RNA were used. Hybridization was performed by standard protocols, using PCR-generated digoxigenin-labeled probes homologous to a number of adenoviral transcripts, all of which were found to be expressed by the wild-type mutant Addl327. The extension of the individual probes is shown in Figure 6 alongside the corresponding Northern blots. Two of the major transcripts essential for viral DNA replication (Adpol and DBP, encoded by the E2 region) were detected at high levels in the type A vectors RR5 and Ad5CMVFIX, both of which show autoreplication, but at far lower levels (DBP) or not at all (AdPol) by Northern blot analysis in the other, nonreplicating vectors (Figure 6d and e). Analogous differences were found for the E1B-14k transcript (complete coding sequence present in all vectors), which was expressed at high levels in type A vectors, but not detectable in type B vectors (Figure 6c ). The E4 region transcript E4-25k was likewise highly expressed in type A, but weakly in type B (Figure 6g ). Late gene expression (L4-100k) was not detectable by Northern analysis in any vector (Figure 6h ). The E1B-55k gene was differentially expressed. Northern blots show three E1B-55k gene transcripts in cells transfected with the wild-type mutant Addl327, which contains the complete E1B-55k coding sequence (Figure 6b) . A short transcript from this region was detected in type A vectors, both of which retain the 3Ј-end of the E1B-55k gene, whereas type B vectors produced no transcript hybridizing to this region, as expected due to its complete deletion in all vectors of this type. No transcripts from the E1A (E1A-32k) or E3 region (E3-14.7k), analyzed as negative controls due to complete deletion of these parts of the E1 and E3 region in all vectors, were detected from any vector (Figure 6a and f) . Figure 7 shows RT-PCR data from experiments analyzing the origin and extension of the viral transcripts from the vectors RR5 and Ad5CMVFIX which hybridized to the E1B-55k gene probe. RT-PCR analysis used coding primers from the 5Ј-terminal region of RR5 or the 5Ј-terminal regions of the cDNAs of the respective transgenes, in conjunction with anticoding primers from the 3Ј-terminal E1B-55k region (Figure 7a Northern blot analyses summarized in Figure 8 show, that in a similar way to RR5 itself and Ad5CMVFIX, all RR5-based vectors ( Figure 8 , lanes 4, 5, 9, 10, 12, 13, 15) transcribe recombinant mRNAs containing transgenic cDNA and the termination signal of the transgene expression cassette plus the residual E1B-55k sequence which is retained in all of these vectors. The variable sizes of the recombinant transcripts are due to the different cDNA lengths of the respective cDNAs (FIX, human coagulation factor IX; cGKI␤, cGMP-dependent protein kinase I␤; hET, human preproendothelin-1, ␣1AT, human ␣1-antitrypsin; GCS␣␤, soluble guanylyl cyclase ␣/␤). Ad5CMVZS2 is an pZS2-based 'empty' control vector containing the pZS2 expression cassette without cDNA. As in Ad5CMVFIX, the transcripts apparently arise from the transgenic CMV promotor. In contrast, recombinant transcripts of this type are not seen in the pJM17-based vectors ( Figure 8 , lanes 3, 6, 11, 16, 17) which do not have autoreplication potential (NOSIII, NO synthase III; cGKI␤, cGKI␤ in pJM17-based vector; GFP, green fluorescent protein). Ad5CMVJM and Ad5CMVPAC are pJM17-based 'empty' control vectors containing pJM17-derived expression cassettes without cDNAs.
In summary, the data outlined in Figures 6, 7 and 8 indicate transcriptional activation of the E1B-14k, adenoviral DNA polymerase, single-strand DNA binding protein, and E4-25k genes in certain adenoviral vectors. They also show differential expression of 'irregular' recombinant transcripts (not occurring in wild-type viruses) in 'type A' autoreplication vectors, but not in nonreplicating 'type B' vectors. Vector autoreplication as detected by the highly sensitive DNA metabolic labeling experiments outlined in Figure 2 is associated with a transcriptional activation of several adenovector genes. 
Discussion
Numerous studies in vivo have shown that transgene expression kinetics are highly variable after gene transfer using recombinant adenoviral vectors. 15 It has been clearly demonstrated that host immune responses against the adenoviral vector itself and its transgene products strongly influence transgene stability (by cytotoxic elimination of vector-transfected cells), and also the efficacy of vector reinjection (by formation of anti-adenovirus neutralizing antibodies). [16] [17] [18] High transgene stability was observed in genetically immunodeficient mice, and significant transgene stabilization was also achieved by different host immunomodulating protocols. 12, 13, 19 Complementary to these direct influences of the host immune system, the structure of the adenoviral vector backbone may indirectly alter transgene stability, with possible immunosuppressive effects of E3 region genes 11, 13, 20 and reduced immunogenicity of E2 region inactivated vectors. 21, 22 Helper-dependent adenovectors devoid of all or nearly all viral genes ('minivectors') have been developed which should have greatly reduced immunogenicity due to minimized production of viral antigens. 23, 24 However, a deletion vector of this type was found to be unstable and to be rapidly lost upon in vivo administration. 23 This rather unexpected finding led to attempts to better understand the molecular mechanism(s) involved in the maintenance of adenovectors in vivo, 23, 25 since such knowledge is essential to direct future adenovector development.
In this context we have addressed a possible basis for the remarkably high stability of adenoviral vector DNA in vivo, which is observed in the absence of host immune responses, ie in genetically immunodeficient hosts. Among different possible explanations (eg stabilization of transgenic DNA by histones) we have investigated the hypothesis of vector DNA 'autoreplication' without production of infectious viral progeny. First, a highly sensitive system for the detection of vector DNA neosynthesis had to be established by using viral DNA metabolic labeling in vector-transfected, non-permissive cells made quiescent to suppress any cellular background of endogenous DNA synthesis. High level production of viral DNA was seen after wild-type adenovirus infection, as expected. In contrast, no vector DNA neosynthesis was detected after transfection with several of the vectors studied, as anticipated because of their extensive E1 region deletions. Unexpectedly, however, several other vectors showed readily detectable autoreplication, ie neosynthesis of vector DNA, in the absence of any formation of infectious viral particles or host cell cytopathic effects. This is of considerable interest, since even limited autoreplication of these vectors in vivo (far below 1% per day) could certainly counteract slow losses of vector DNA in the host cell over long time-periods of months or even years, and could thus significantly stabilize the transgene. Autoreplication was observed in different nonpermissive cell lines, suggesting that the phenomenon is not unique to a single cell type. It must be emphasized, however, that the kinetics of autoreplication may well be influenced by the host cell type and also by the number of vector molecules present in a cell which in turn influence the amount of viral transcribed sequences. The highly sensitive vector DNA metabolic labeling experiments (Figure 2 ) and the quantitative PCR analyses (Figure 3c ) of adenovector DNA in cell cultures clearly indicate differential neosynthesis of vector genomes and provide a rational basis for further in vivo investigations of transgene stabilization by autoreplication. The primary parameter in these studies will not be the transgene expression level which is strongly influenced by vector backbone-independent factors, but the number of vector DNA molecules persisting per cell over time. Direct detection of autoreplication in vivo by vector DNA metabolic labeling such as used in our cell culture studies, eg in mouse liver after intravenous vector injection, should most probably be impossible for technical reasons due to the low rate of vector DNA neosynthesis against a strong background of endogenous hepatocellular DNA synthesis. The described quantitative PCR assay of vector DNA, however, is useful for sensitive indirect detection of autoreplication capacity. An important recent paper addressing the molecular basis of adenoviral vector stability 26 suggested, that persistence of recombinant adenovirus in vivo is not dependent on vector DNA replication. The elegant method of tagging the adenoviral vector genome by site-specific methylation of Xhol restriction sites employed in that study, however, was considered by the authors themselves to be not sensitive enough to exclude low level vector DNA neosynthesis which, on the other hand, would be completely sufficient to counteract slow losses of vector over time. Since the sensitive DNA metabolic labeling technique cannot be applied in vivo, and methylation tagging of vector DNA is not sufficiently sensitive, 26 indirect detection of autoreplication by quantitative PCR is an interesting alternative.
Since autoreplication was associated with high transcriptional activity of several viral genes, adverse effects on host cell function or immunogenicity cannot be excluded so far, although an in vivo study of the autoreplication type vector Ad5CMVFIX in mouse liver 13 did not reveal any adverse long-term effects in the target organ after 1 year of transgene expression (no liver pathology as assessed by conventional and immunohistology, unpublished data). In order to put the suggested transgene stabilizing potential of vector autoreplication into perspective it should be mentioned, that in immunodeficient mice both type A and type B vectors as defined here show high stability. [11] [12] [13] 19 It thus appears, that in the absence of a functional immune system adenoviral vector genomes in fact do have an inherently high stability, and that transgene stabilizing effects of autoreplication could only become relevant under the more restrictive conditions of immunocompetent hosts. This is the common situation in gene therapy settings, however.
When considering a possible molecular basis for the autoreplication potential of the RR5 and Ad5CMVFIX
Figure 5 DNA sequence analysis of the E1 region in different adenoviral vectors. The sequence of the vector RR5 and its recombinants derived by using the transfer plasmid pZS2 (top line) is compared with that of recombinant vectors derived by homologous recombination between pJM17 and the transfer plasmid pCMVI (middle), and with wild-type Ad5 sequence (bottom line). Sequence numbering is given as in the adenovirus 5 wild-type sequence, wild-type sequences preserved in the vectors are boxed, whereas the extension of the deletions of the wild-type sequence in the respective vectors are indicated by points. Nucleotide 560 is the first base pair of the start codon of the E1 region E1A-32k gene (see Figure 1). The E1A region is completely deleted in both RR5-based and pJM17-based vectors. The E1B region is only partially deleted in both cases. In both cases the deletion includes the first base of the E1B-55k start codon, but whereas RR5-based vectors retain part of the 3Ј-end of the E1B-55k gene from np 3334 to the stop codon at np 3508, pJM17-based constructs are delected beyond the stop codon up to np 3523. The complete E1B-14k gene coding sequence starting at np 3608 is conserved in both cases.
vector, detection of enhanced viral gene expression plus recombinant transcripts is of interest. Commonly used adenoviral vectors maintain residual transcriptional activity of some viral genes, 21 the products of which may enhance immunogenicity as shown for the DNA-binding protein. 21 ,27,28 DBP transcription from E1-deleted vectors was confirmed in this study. In addition, a number of viral sequences (E1B-14k, AdPol, E4-25k, part of E1B-55k) were found to be expressed at high levels in the autoreplication (type A) vectors investigated, whereas transcripts from these genes were detected at low levels or not at all from non-replicating (type B) vectors. In addition, recombinant transcripts were detected, but only in type A vectors. In the case of RR5, this transcript starts from 5Ј-terminal adenoviral sequences, in Ad5CMVFIX it originates from the strong exogenous CMV promotor of the transgene expression cassette, and in both cases extends into the residual adenoviral E1B-55k sequences. Similar recombinant transcripts were also seen in all other RR5-based vectors, but in none of the pJM17-based vectors studied. In summary, the data are consistent with the hypothesis, that exogenous or cryptic promotors enhance (under certain conditions) the transcriptional activity of a vector in such a way that autoreplication occurs, and that the residual E1B-55k sequence retained in RR5-based but not in pJM17-based vectors plays an essential role here. Therefore, the molecular consequences of the obvious transcription of the E1B-55k gene fragment should be further investigated. Possibly, type and strength of the promotor and termination signal of the expression cassette, and the specific transgenic cDNA expressed also influence transcriptional activation. All these complex factors should now be analyzed in further detail so that rational design of vectors with autoreplication capacity (ie vector genome neosynthesis without production of infectious progeny) becomes possible. Modification of the viral E1 region to generate novel functional properties of the resulting vector has been applied previously, in one case to achieve tumor-specific cytolysis and antitumoral efficacy (vector ONYX-015), 29 in another to achieve selective vector replication in non-small cell lung cancer. 30 When considering possible mechanisms for autoreplication, the recent demonstration that E1-deleted adenoviral vectors can induce NFb at high MOI and thereby increase transcription of NFb-dependent genes in the target cells 31 is of interest. Vector sequences responsible for NFb induction have not been identified so far, but obviously even E1-deleted vectors retain at least one such sequence capable of inducing a transcription factor which strongly modulates the transcription pattern of the host cell genome, and possibly also of viral vector genes. To our knowledge, NFb has not been shown so far to upregulate autoreplication-associated transcripts (E1B-14k, DBP, AdPol, E4-25k, E1B-55k), so that any role in autoreplication is uncertain. Whether transcription factors other than NFb 31 and/or short RNA sequences 32, 24 are involved in the process of autoreplication requires further analysis. It should be noted, that even at high MOI type B vectors did not show any autoreplication in the DNA metabolic labeling studies, whereas type A vectors showed high level vector DNA neosynthesis under these same conditions. Autoreplication does not necessarily occur at high MOI, but clearly requires specific but still not completely defined properties of the vector genome. Upon definition of the minimal adenoviral sequences required for autoreplication very high minivectors with packaging capacity which still retain this feature could be designed.
In summary, autoreplication has been shown here to be a novel feature of certain E1-deleted adenovectors with likely relevance for their stability in vivo, but possibly adverse consequences for target cell function or vector immunogenicity cannot be excluded. Full characterization of adenoviral vector systems should therefore include a description of their autoreplication capacity, in particular when vectors with extensive deletions (minivectors) are investigated. It remains to be seen how the in vivo properties of virus-based autoreplication vectors with their high gene transfer efficacy compare with those of 'mammalian artificial chromosome' type vectors with plasmid structure. Both strategies attempt to realize the important new concept of an episomal vector endowed with the capacity of self-renewal. 
untransfected control cells). E1B-14k transcript levels in type A vectors were similar to those in the wild-type mutant Addl327 (lane 2). The E4-25k gene was likewise highly expressed in type A, however, weakly in type B vectors (g). Late gene L4-100k expression was not detectable by Northern analysis in any vector, but only in Addl327 (h). A probe homologous to the 3Ј-terminal end of E1B-55k (present in Addl327 and in type A vectors) showed more complex hybridization patterns: three transcripts of different sizes were observed in Addl327-transfected cells (b, lane 2). A single short transcript was detected in type A vectors (lanes 3 and 5), which retain the 3Ј-end of the E1B-55k sequence, whereas type B vectors (lanes 2 and 4) produced no transcript from this region, as expected. Probes for the E1A-32k and the E3-14.7k genes were analyzed as negative controls (complete deletion of these parts of E1 and E3 in all vectors) (a and f). With respect to the transcript levels of Addl327 it should be noted that the wild-type mutant Addl327 enters a normal lytic cycle, whereas the E1-deleted vectors do not. Early and late gene expression levels are highly dynamic for Addl327 (cell lysis induced within 2 days) and therefore not directly comparable with the stable expression levels of the non-lytic vectors.

Materials and methods
Development of recombinant adenoviral vectors
Development of recombinant type A vectors: Foreign cDNAs of interest were excised and inserted into the eukaryotic expression plasmid pZS2, which contains viral sequences reaching from the adenoviral 5Ј-ITR to np 445, followed by a CMV promotor, a polylinker, bovine growth hormone gene termination signals and a unique XbaI restriction site used for in vitro ligation of the linearized plasmid with RR5, an Addl309-derived adenovirus mutant with a deletion of the E1 region ranging from np 445-3333, and a unique XbaI site upstream of this deletion. RR5 was propagated in 293 human embryonic kidney cells and then isolated by banding in caesium chloride gradients, followed by desalting on Sephadex G-25 columns (Phamacia, Freiburg, Germany). RR5 genomic DNA was isolated from the purified virus preparation and then restricted with Xbal. This releases a 445-kb 5Ј-terminal XbaI fragment of the RR5 genome, which is then separated from the large 3Ј-XbaI fragment using ultracentrifugation through a 10-40% sucrose gradient. The long XbaI fragment was ligated with the recombinant pZS2 expression plasmid of interest and then transfected into 293 cells using the calcium phosphate method. Viral plaques appeared between 12 and 15 days of cell culture. After complete lysis of virus-containing cell cultures, standard plaque purification of the lysate material was performed using confluent 293 cell cultures overlaid with low melting point agarose (Sigma, Deisenhofen, Germany). After 5-7 days single plaques appeared under the agarose overlay, which were picked and processed for PCR screening: the plaque material plus agarose was subjected to three cycles of freezing and thawing, incubated for 30 min at 37°C in lysis buffer (ammonium sulfate 16.6 mm, Tris-HCl pH 8.8 6.7 mm, MgCl 2 6.7 mm, 2-mercaptoethanol 5 mm, EDTA 6.7 mm, SDS 1.7 mm, proteinase K 50 g/ml), then inactivated at 85°C for 10 min. DNA was finally isolated from the lysate by standard phenol/chloroform extraction. Using this DNA as the template recombinant plaques harboring the vector of interest were identified by PCR analysis. PCR conditions were: initial denaturation for 5 min at 94°C, then 30 cycles with 1 min denaturation at 94°C, 1 min annealing at 55-73°C, 2 min 30 s (plus 10 s per cycle of extension) at 72°C, and a final extension step of 10 min. PCR-positive clones were subsequently purified by two additional cycles of standard plaque purification. Details of 'type A' vectors are as follow: Ad5CMVFIX is an RR5-based recombinant vector expressing a cDNA encoding the human coagulation factor IX, as described previously.
Figure 7 RT-PCR analysis of recombinant mRNA transcripts from autoreplication (type A) adenoviral vectors. RT-PCR data from experiments analyzing origin and extension of viral transcripts from the vectors RR5 and Ad5CMVFIX which are homologous to the E1B-55k gene probe (compare Figure 6b). RNA isolated from EAhy.926 cells transfected with different vectors was subjected to RT-PCR by using coding primers from the 5Ј-terminal region of wild-type adenovirus (for RR5 and Add1327) and the 5Ј-terminal regions of the respective transgene cDNAs (Ad5CMVFIX, NOSIII, cGKI␤), respectively, in conjunction with anticoding primers from the 3Ј-terminal E1B-55k region (a) or coding primers from the termination signal sequence of the expression cassette together with the anticoding 3Ј-terminal E1B-55k primer (b). 'A' and 'B' below the lanes designate type A and B vectors, respectively. 'W' designates Addl327 as wild-type mutant, 'NT' are uninfected control cells. (a) RT-PCR detection of recombinant transcripts from RR5 (lane 3) and
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Ad5CMVcGKI␤* is an RR5-based vector expressing a cDNA encoding the human cGMP-dependent protein kinase type I␤, as described. 33, 34 This vector expresses the same cDNA as the pJM17-based 'type B' vector Ad5CMVcGKI␤ described below. Ad5CMVppET-1 is an RR5-derived vector encoding the early precursor molecule of human endothelin-1 (preproendothelin-1) and has been shown to express biologically active mature endothelin-1. 35 Ad5CMV␣1AT is also RR5-based and expresses the human proteinase inhibitor ␣1-antitrypsin. 36 The vectors Ad5CMVGCS␣ and Ad5CMVGCS␤ express the two components (␣, ␤) of soluble guanylyl cyclase (GC), the cellular receptor of nitric oxide, and produce functional GC when co-expressed (Schmidt and Poller, unpublished data). Ad5CMVZS2 is an pZS2-based 'empty' control vector containing the pZS2 expression cassette without any cDNA.
Development of type B vectors:
A plasmid pCMVI was constructed by cloning the expression cassette from the plasmid pCI (Promega, Heidelberg, Germany), containing a CMV promotor and a SV40 termination signal, into the adenoviral transfer plasmid p⌬E1sp1A (Microbix, Toronto, Canada). Foreign cDNAs of interest were inserted into pCMVI. The resulting expression plasmids were subsequently cotransfected together with the circularized adenoviral genome pJM17 (Microbix) into 293 cells. Viral plaques appeared between 10 and 20 days after transfection. PCR screening for recombinant virus was done similarly as described above. Details of 'type B' vectors are as follows: Ad5CMVNOSIII is a pJM17-based recombinant vector expressing the endothelial cell nitric oxide synthase type III, 35 Ad5CMVcGKI␤ is the pJM17-based analogon of the above described RR5-based vector Ad5CMVcGKI␤*. Ad5CMVGFP is a similarly constructed vector expressing the marker gene encoding green fluorescent protein. Ad5CMVJM and Ad5CMVPAC are pJM17-based 'empty' control vectors containing pJM17-derived expression cassettes without cDNAs. The RR5 vector system and a recombinant vector expressing firefly luciferase (Ad5CMVLuc) were generous gifts from R Gerard and J Herz (Southwestern Medical Center, Dallas, TX, USA).
Cell cultures 293 and COS7 cells were grown in Dulbecco's modified Eagle's medium (DMEM) (GIBCO/Life Technologies, Eggenstein, Germany) containing 4.5 g/l glucose, 10% fetal calf serum, 100 IU/ml penicillin and 100 g/ml streptomycin. 293 cells were used for the cloning and 4, 5, 9, 10, 12, 13, 15) 3, 6, 11, 16, 17 amplification of recombinant adenoviral vectors and for plaque assays using standard methods. EA.hy926 cells are stable hybrids resulting from fusion of primary human umbilical vein endothelial cells (HUVECs) with a human epithelial cell line (A549). The cells were grown in DMEM containing 4.5 g/l glucose, 0.2 mg/l aminopterin, 13.6 mg/l hypoxanthin, 3.9 mg/l thymidine, 10% fetal calf serum, 100 IU/ml penicillin and 100 g/ml streptomycin. EA.hy926 cells were used for adenoviral gene transfer experiments when confluent. COS7 cells were also used for adenoviral gene transfer after reaching confluency.
For the assessment of the stability of vector DNA in proliferating cells by quantitative PCR, EAhy.926 cells were seeded at low density (10 4 cells per cm 2 ) on large cell culture plates (diameter 20 cm) and transfected with different vectors at a MOI of 10, thus the input quantity of vector DNA was similar in all cases. Under these conditions the target cells proliferated rapidly and became confluent on day 4. Quantitative PCR analyses of vector DNA as described below were then performed on day 6 after transfection. The results of these assays are a measure of vector quantity per cell, since the adenovector DNA quantity detected is related to the GAPDH genomic DNA quantity which in turn is constant per cell (two copies of the gene + two copies of each pseudogene).
Assessment of vector cytotoxicity
Potential cytotoxicity of the vectors was assessed by morphological analysis and by LDH release assay using a Cytotoxicity Detection Kit (Boehringer, Mannheim, Germany). EAhy.926 cells were infected with different vectors at two doses (MOI = 10 or 100). Twenty-four hours later, three aliquots of 100 l medium each were removed from each of the infected cultures, LDH assay reaction mix was added, and LDH activity was determined by measuring extinction at 490 nm in triplicate for each vector. Cells pretreated with 1% Triton X-100 served as positive controls.
Vector DNA metabolic labeling Radioactive DNA metabolic labeling in cell cultures infected with adenoviral vectors was performed as follows. To make cells quiescent and thus to suppress host cell DNA neosynthesis, cell monolayers were used 5 days after becoming confluent, then washed with PBS and incubated with thymidine-free medium for 24 h. The cells were then infected with CsCl-purified adenoviral vectors at an MOI of 100. Eleven hours after infection, 1 mCi/ml of thymidine-6-3 H with a specific activity of 20-40 Ci/mmol (ICN, Meckenheim, Germany) was added. Six hours after labeling the maintenance medium was removed. The cells were washed twice with PBS and total cellular DNA isolation was done similarly as described for the development of adenoviral vectors.
Vector DNA detection After transfection of target cells with different adenoviral vectors as described above in 'vector DNA metabolic labeling,' viral genomic DNA of the recombinant vectors was detected in the total nuclear DNA of the target cells by using Southern blot and PCR analyses.
PCR amplification: Detection of non-radiolabeled vector DNA was performed by using three different methods. For standard PCR detection, 1 g of nuclear DNA was used as a template for PCR amplification of the vector DNA by using the following primer pairs: 5Ј-TGATAAT-GAGGGGGTGGAGTTTGT-3Ј (Ad5-code) with 5Ј-TC TCTCAAGGTTCCCTTGAAC-3Ј (FIX-anti) for detection of Ad5CMVFIX, 5Ј-AACTCGACCATCTCTACCGCGA CGA-3Ј (NOSIII-code) with 5Ј-CCGGTAAAGGCCAA-
CAGGACA-3Ј
(NOSIII-anti) for detection of Ad5CMVNOSIII, 5Ј-TGATAATGAGGGGGTGGAGTTT GT-3Ј (Ad5-code) with 5Ј-TGGACTGTGGGCTCTT GGAGA-3Ј (cGKl␤-anti) for detection of Ad5CMVcGKI␤ and 5Ј-TGACCAAGCAGTTCCAGGCG-3Ј (Ad5-code1) with 5Ј-CGTGCAGCTAAACATCGCGG-3Ј (Ad5-anti) for detection of adenoviral vectors. PCR conditions were as described above in 'Development of recombinant adenoviral vectors'.
Quantitative PCR analysis: For a quantitative analysis of adenoviral vector DNA using a quantitative competitive PCR assay (qPCR), 37 an external adenovirus standard carrying a 10-base pair deletion was generated by overlap extension PCR. 38 The following primer pairs were used for the two primary PCRs: Adstndcode 5Ј-CCCA-CAGCTCGGTCACCTGC-3Ј (np 5176-5195 of the adenovirus type 5 genome) with Admutanti 5Ј-CTGGAC-GAGCACCGAACAGCGAAAGCCGCCCCAAC-3Ј (np 5236-5284), and Admutcode 5Ј-GGCGGCTTTCGCT GTTCGGTGCTCGTCCAGACGGG-3Ј (np 5241-5284) with Adstndanti 5Ј-GACTACGCTGACGAGGACCC-3Ј (np 5313-5332). There followed a secondary 'overlap mutagenesis' PCR using the two products of the primary PCRs as templates and the primer pair Adstndcode with Adstndanti. The resulting 10-bp-deleted adenoviral DNA segment (from a region conserved in all recombinant vectors used in this study) was then cloned into the plasmid pCR-script (Stratagene, Heidelberg, Germany). A 10-bpdeleted GAPDH standard plasmid generated by an analogous technique and described previously 37 was kindly provided by M Watzka (Haemophilia Center, University of Bonn, Germany). For qPCR the mutant adenoviral and GAPDH pCR-script clones were used as standards. qPCR was performed with 200 ng of total nuclear DNA extracted from vector-transfected cells and defined amounts (1 ng, 100 pg, 10 pg, 1 pg) of adenoviral and GAPDH standard, respectively. Separate PCRs were performed for adenoviral and GAPDH DNA sequences in a final volume of 20 l containing 2 l PCR buffer (Perkin Elmer/Applied Biosystems, Weiterstadt, Germany), 1.5 U AmpliTaq (Perkin Elmer), 200 m of each dNTP, 10 pmol of each primer. PCR was performed on a GeneAmp PCR System 9700 (Perkin Elmer). For detection of the adenoviral target sequence, the fluorescence labeled primer 5Ј-CGGCATCTCGATCCAGCATATCTCCT-3Ј (Ad5-FAMcode) and the unlabeled primer 5Ј-GACTACGCTGAC-GAGGACCC-3Ј (Adstndanti) were used. The reaction mix was initially denatured at 94°C for 5 min, then followed 30 cycles of denaturation at 94°C for 40 s, annealing at 55°C for 30 s, and extension at 72°C for 35 s. The PCR ended with a final extension step at 72°C for 7 min, yielding the PCR products pAd5 and pAd5⌬10. For detection of the GAPDH target sequence, the fluorescence-labeled primer 5Ј-TGCCAAGGCTG TGGGCAAGG-3Ј (GAPDH-TAMRA-code) and the unlabeled primer 5Ј-GCTTCACCACCTTCTTGATG-3Ј (GAPDH-anti) 37 were used. There was initial denaturation as above, followed by 30 cycles of denaturation at 94°C for 30 s, annealing at 62°C for 40 s, and extension at 72°C for 30 s. The PCR ended with a final extension step at 72°C for 5 min, yielding the PCR products pGAPDH and pGAPDH⌬10. FAM and TAMRA are different fluorescence labels (Perkin Elmer). The fluorescence-labeled amplification products were detected by capillary electrophoresis using Polymer 4 (Perkin Elmer) on an ABI 310 Genetic Analyzer (Applied Biosystems). The ABI collection software creates peaks for each signal, with height and area of each peak depending on signal intensity. Peak areas were calculated using the Genescan software (Applied Biosystems). The ratio R 1 between adenoviral target sequence PCR product pAd5 (undeleted) and the adenoviral standard plasmid PCR product pAd5⌬10 (10-bp-deleted) was used to determine the viral DNA concentration in vector-transfected cells. Any variation in the actual cellular DNA quantities subjected to the PCR were considered by calculating the ratio R 2 between the GAPDH target sequence PCR product pGAPDH (undeleted) and the GAPDH standard plasmid PCR product pGAPDH⌬10 (10-bp-deleted). Then a normalized value R for vector DNA concentration per target cell could be calculated as R = (R 1 × concentration of Ad5⌬10 standard): (R 2 × concentration of GAPDH⌬10 standard). The value R is proportional to the vector copy number per cell.
Southern blot analysis:
To exclude the theoretical possibility of differential degrees of DNA fragmentation of type A versus type B vectors after entry into target cells, Southern blot analysis was used as a third independent method for vector DNA quantification. 10 g of nuclear DNA was subjected to HindIII restriction, fractionated on 1% agarose gel, and blotted on to Hybond Nylon Plus membrane (Quiagen, Hilden, Germany). A probe detecting a sequence common to all vectors used (base pairs 4385-5905 of the wild-type adenovirus sequence) was prepared using a digoxigenin high prime DNA labeling and detection kit (Boehringer). Prehybridization, hybridization, and immunologic detection of the target DNA were performed according to the manufacturer's protocol.
Adenoviral vector DNA sequence analysis Viral genomic DNA was isolated from the respective adenoviral vectors as described above. The E1 region of RR5 was amplified for sequencing by using the primer pair 5Ј-TGATAATGAGGGGGTGGAGTTTGT-3Ј (Ad5-code) with 5Ј-AGCCTTCAGGGCAGAAACCT-3Ј (Ad5-E1-anti) Sequencing was done using dye-labeled oligonucleotide primers, a cycle-sequencing protocol, and subsequent analysis on an ABI Prism 310B Genetic Analyzer (Applied Biosystems).
Analysis of transcriptional activity from viral vectors
For Northern blot analysis, total cellular RNA was extracted from adenovector-transfected cells by using the Trizol system (GIBCO). RNA samples (20 g each) were then size-fractioned on 1.5% agarose gels containing 17% formaldehyde, blotted on to Hybond Nylon Plus membranes and cross-linked by UV irradiation. PCRgenerated probes for the viral sequences of interest were digoxigenin-labeled by random hexanucleotide priming (Boehringer) and used for Northern hybridization by standard protocols. Probes for hybridization were amplified from adenoviral wild-type DNA by using the following primer pairs: 5Ј-AACCTGAGCCTGAGCCCGAG-3Ј (E1A-32k-code) with 5Ј-ACGCCCACCAACTCTCA-CGG-3Ј (E1A-32k-anti) for E1A-32k (np 1241-1442); 5Ј-CCTGCGAGTGTGGCGGTAAA-3Ј (E1B-55k-code) with 5Ј-CAAACTCAGCGGGGGTGCAG-3Ј (E1B-55k-anti) for 
